Abstract Library

#4572 Steroid dosing to prevent tumour flare reaction with 177Lu-DOTATATE

Introduction: Tumour flare reactions including increased pain and small bowel obstruction (SBO) have been reported in patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) receiving 177Lu-DOTATATE. Retrospective reviews report tumour flare reactions in 6 to 40 percent of high-risk patients receiving 177Lu-DOTATATE and report success with using corticosteroid prophylaxis to prevent tumour flare recurrence with subsequent doses of 177Lu-DOTATATE (Strosberg, et al., 2021; Salner, et al., 2020).

Conference:

Presenting Author:

Authors: Cass A, Skotte E, Wheless M, Stockton S, Ramirez R,

Keywords: 177Lu-DOTATATE, corticosteroid prophylaxis, tumour flare,

#4566 Predictive value of high-risk histopathological- and molecular criteria for lymph node metastasis in appendiceal neuroendocrine tumours

Introduction: Appendiceal neuroendocrine tumours (aNET) are rare neoplasms for which consensus is needed for follow-up and additional treatment. To unravel the factors behind aNET which showed lymph node metastasis (LNM) in additional right hemicolectomy (RH), we evaluated high-risk histopathological parameters in aNETs and studied molecular parameters.

Conference:

Presenting Author: Bremer B

Authors: Bremer B, Kyriskozoglou V, El Moumni M, Heideman D, Walenkamp-Hageman A,

Keywords: Appendix NET, High-risk histopathological criteria, Serotonin, Driver mutation, Right Hemicolectomy,

#4524 SIRT7 drives the radioresistance of pancreatic neuroendocrine tumours via the DNMT1-MEN1 axis

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are a rare and highly heterogeneous type of tumour in the pancreas. After failure of standard treatment, patients have poor prognoses. Radiotherapy may be a potential therapeutic modality for such patients. However, PanNETs usually exhibit a radiation “cold” tumour through unclarified mechanisms.

Conference:

Presenting Author: Jianyun J

Authors: Jiang J, Xu J, Liang Y, Chen L, Ji S,

Keywords: pancreatic neuroendocrine tumour, radio resistance, SIRT7, MEN1,

#4485 Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms (NEN) treated with [177Lu]Lu-DOTA-Octreotate (LuTate) therapy over a 4.5 year period at a single high volume treatment centre

Introduction: LuTate therapy is an effective treatment for patients with somatostatin receptor expressing NEN. However, patients (pts) with functional tumours may develop an acute flare of symptoms during or after PRRT.

Conference:

Presenting Author: Kong G

Authors: Neeson L, Boehm E, Chiang C, Michael M, Sachithanandan N,

Keywords: PRRT, NET, high-risk, flare, outcomes, NEN, single centre,

#4292 Predictors based on the radiologic characteristics for aggressiveness of small (＜20 mm) non-functioning pancreatic neuroendocrine tumours

Introduction: The management of small non-functioning PNETs remains controversial due to their heterogeneity. Results from some retrospective surgical reports found that a subset of small NF-PNETs may show aggressive behaviour, for which surgical resection is recommended.

Conference:

Presenting Author: Shu-Jie R

Authors: Ren S, Fan Y, Tan C, Wang X, Tan Q,

Keywords: small pancreatic neuroendocrine tumour, high-risk factor, radiologic characteristics, tumour marker, prognostic factor,